Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.89
DRRX's Cash to Debt is ranked lower than
53% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. DRRX: 1.89 )
Ranked among companies with meaningful Cash to Debt only.
DRRX' s 10-Year Cash to Debt Range
Min: 0.63  Med: 22.07 Max: No Debt
Current: 1.89
Equity to Asset 0.43
DRRX's Equity to Asset is ranked lower than
77% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DRRX: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
DRRX' s 10-Year Equity to Asset Range
Min: 0.07  Med: 0.46 Max: 0.96
Current: 0.43
0.07
0.96
F-Score: 4
Z-Score: -5.45
M-Score: -3.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -120.12
DRRX's Operating margin (%) is ranked lower than
90% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. DRRX: -120.12 )
Ranked among companies with meaningful Operating margin (%) only.
DRRX' s 10-Year Operating margin (%) Range
Min: -10882.56  Med: -140.83 Max: 30.25
Current: -120.12
-10882.56
30.25
Net-margin (%) -131.69
DRRX's Net-margin (%) is ranked lower than
91% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. DRRX: -131.69 )
Ranked among companies with meaningful Net-margin (%) only.
DRRX' s 10-Year Net-margin (%) Range
Min: -10125.58  Med: -146.10 Max: 30.53
Current: -131.69
-10125.58
30.53
ROE (%) -110.72
DRRX's ROE (%) is ranked lower than
95% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. DRRX: -110.72 )
Ranked among companies with meaningful ROE (%) only.
DRRX' s 10-Year ROE (%) Range
Min: -208.92  Med: -67.97 Max: 81.39
Current: -110.72
-208.92
81.39
ROA (%) -45.81
DRRX's ROA (%) is ranked lower than
91% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. DRRX: -45.81 )
Ranked among companies with meaningful ROA (%) only.
DRRX' s 10-Year ROA (%) Range
Min: -55.27  Med: -32.14 Max: 34.06
Current: -45.81
-55.27
34.06
ROC (Joel Greenblatt) (%) -748.81
DRRX's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. DRRX: -748.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -977.57  Med: -529.98 Max: 500.45
Current: -748.81
-977.57
500.45
Revenue Growth (3Y)(%) -23.50
DRRX's Revenue Growth (3Y)(%) is ranked lower than
93% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DRRX: -23.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 2.80 Max: 52.3
Current: -23.5
0
52.3
EBITDA Growth (3Y)(%) -3.50
DRRX's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. DRRX: -3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DRRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.8  Med: -6.35 Max: 39.2
Current: -3.5
-35.8
39.2
EPS Growth (3Y)(%) -1.60
DRRX's EPS Growth (3Y)(%) is ranked lower than
59% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DRRX: -1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DRRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.3  Med: -10.20 Max: 27.7
Current: -1.6
-28.3
27.7
» DRRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

DRRX Guru Trades in Q3 2014

Jim Simons 27,200 sh (New)
Robert Bruce 1,215,973 sh (unchged)
First Eagle Investment 10,707,142 sh (unchged)
» More
Q4 2014

DRRX Guru Trades in Q4 2014

First Eagle Investment 10,707,142 sh (unchged)
Robert Bruce 1,215,973 sh (unchged)
First Eagle Investment 10,707,142 sh (unchged)
Jim Simons 17,800 sh (-34.56%)
» More
Q1 2015

DRRX Guru Trades in Q1 2015

Jim Simons 58,700 sh (+229.78%)
First Eagle Investment 13,196,397 sh (+23.25%)
First Eagle Investment 13,129,197 sh (+22.62%)
Robert Bruce 1,215,973 sh (unchged)
» More
Q2 2015

DRRX Guru Trades in Q2 2015

Jim Simons 227,100 sh (+286.88%)
First Eagle Investment 13,196,397 sh (unchged)
Robert Bruce 863,609 sh (-28.98%)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Durect Corp

Jean-Marie Eveillard Ups Stake in Pharma Company Durect
Former portfolio manager at First Eagle Funds, Jean-Marie Eveillard (Trades, Portfolio), increased his stake in Durect Corp (NASDAQ:DRRX) on March 9 by more than 22%, according to GuruFocus’ Real Time Picks. Read more...

Ratios

vs
industry
vs
history
Forward P/E 5.73
DRRX's Forward P/E is ranked higher than
97% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. DRRX: 5.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 11.05
DRRX's P/B is ranked lower than
91% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. DRRX: 11.05 )
Ranked among companies with meaningful P/B only.
DRRX' s 10-Year P/B Range
Min: 1.69  Med: 7.85 Max: 38.38
Current: 11.05
1.69
38.38
P/S 13.13
DRRX's P/S is ranked lower than
87% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. DRRX: 13.13 )
Ranked among companies with meaningful P/S only.
DRRX' s 10-Year P/S Range
Min: 0.93  Med: 8.89 Max: 20.19
Current: 13.13
0.93
20.19
Current Ratio 7.96
DRRX's Current Ratio is ranked higher than
86% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. DRRX: 7.96 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s 10-Year Current Ratio Range
Min: 1.48  Med: 5.72 Max: 29.59
Current: 7.96
1.48
29.59
Quick Ratio 7.26
DRRX's Quick Ratio is ranked higher than
86% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. DRRX: 7.26 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s 10-Year Quick Ratio Range
Min: 1.41  Med: 5.39 Max: 28.73
Current: 7.26
1.41
28.73
Days Inventory 259.24
DRRX's Days Inventory is ranked lower than
92% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. DRRX: 259.24 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s 10-Year Days Inventory Range
Min: 211.18  Med: 244.16 Max: 405.71
Current: 259.24
211.18
405.71
Days Sales Outstanding 39.11
DRRX's Days Sales Outstanding is ranked higher than
80% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. DRRX: 39.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s 10-Year Days Sales Outstanding Range
Min: 14.9  Med: 46.86 Max: 411.69
Current: 39.11
14.9
411.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 35.00
DRRX's Price/Net Cash is ranked lower than
81% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. DRRX: 35.00 )
Ranked among companies with meaningful Price/Net Cash only.
DRRX' s 10-Year Price/Net Cash Range
Min: 2.33  Med: 16.51 Max: 525
Current: 35
2.33
525
Price/Net Current Asset Value 17.50
DRRX's Price/Net Current Asset Value is ranked lower than
80% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. DRRX: 17.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.03  Med: 11.17 Max: 172.5
Current: 17.5
2.03
172.5
Price/Tangible Book 15.00
DRRX's Price/Tangible Book is ranked lower than
91% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. DRRX: 15.00 )
Ranked among companies with meaningful Price/Tangible Book only.
DRRX' s 10-Year Price/Tangible Book Range
Min: 1.37  Med: 7.78 Max: 203
Current: 15
1.37
203
Price/Median PS Value 1.48
DRRX's Price/Median PS Value is ranked lower than
62% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. DRRX: 1.48 )
Ranked among companies with meaningful Price/Median PS Value only.
DRRX' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 1.24 Max: 10.56
Current: 1.48
0.12
10.56
Earnings Yield (Greenblatt) (%) -9.00
DRRX's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DRRX: -9.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 17.1  Med: 29.25 Max: 48.2
Current: -9
17.1
48.2

Analyst Estimate

Dec15 Dec16
EPS($) -0.25 -0.23
EPS without NRI($) -0.25 -0.23

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DC8.Germany,
Durect Corp was incorporated in Delaware in February 1998. The Company is a specialty pharmaceutical company engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company's product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company's development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. POSIDUR, SABER, CLOUD, TRANSDUR, ORADUR, ELADUR, DURIN, CHRONOGESIC, MICRODUR, ALZET and LACTEL are the trademarks of the Company. The manufacturing and marketing of its pharmaceutical systems and its research and development activities are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad.
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard and Arnold Van Den Berg Raise Stakes in Small-Cap Stocks Mar 24 2015 
Jean-Marie Eveillard Ups Stake in Pharma Company Durect Mar 23 2015 
Durect Corp. Reports Operating Results (10-Q) Nov 04 2010 
Durect Corp. Reports Operating Results (10-Q) Aug 05 2010 
Opportunistic Coat-tailing Jan 05 2010 
Durect Corp. Reports Operating Results (10-Q) Nov 02 2009 
Durect Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
DURECT to Participate in Upcoming Healthcare Conferences Aug 27 2015
DURECT to Participate in Upcoming Healthcare Conferences Aug 27 2015
Energy Sector Dominates Robert Bruce's Second-Quarter Activity Aug 19 2015
DURECT CORP Financials Aug 11 2015
10-Q for DURECT Corp. Aug 06 2015
DURECT CORP Files SEC form 10-Q, Quarterly Report Aug 04 2015
Edited Transcript of DRRX earnings conference call or presentation 3-Aug-15 8:30pm GMT Aug 03 2015
Durect reports 2Q loss Aug 03 2015
Durect reports 2Q loss Aug 03 2015
DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs Aug 03 2015
DURECT Corp Earnings Call scheduled for 4:30 pm ET today Aug 03 2015
DURECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2015
DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs Aug 03 2015
Q2 2015 DURECT Corp Earnings Release - After Market Close Aug 03 2015
DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference Call Jul 24 2015
DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference Call Jul 24 2015
Cancer Prevention Pharmaceuticals, Inc. Announces Appointment of Jon S. Saxe to its Board of... Jul 23 2015
DURECT to Present at the Cantor Fitzgerald Healthcare Conference Jun 29 2015
DURECT to Present at the Cantor Fitzgerald Healthcare Conference Jun 29 2015
Cantor Analyst: Durect Is Worth $3/Share, So Buy It Jun 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK